Misplaced Pages

Salubrinal: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 20:48, 20 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProj← Previous edit Latest revision as of 17:08, 21 January 2025 edit undoFswitzer4 (talk | contribs)Extended confirmed users10,990 editsm Added UNII ID 
(34 intermediate revisions by 20 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
⚫ | verifiedrevid = 447295874
| Watchedfields = changed
⚫ | verifiedrevid = 451564438
| IUPAC_name = 3-phenyl-''N''-[2,2,2-trichloro-1-[[(8-quinolinylamino)thioxomethyl]amino]ethyl]-2-propenamide | IUPAC_name = 3-phenyl-''N''-[2,2,2-trichloro-1-[[(8-quinolinylamino)thioxomethyl]amino]ethyl]-2-propenamide
| image = Salubrinal.svg | image = Salubrinal.svg
| width = 200 | width =
| alt = | alt =
| image2 = | image2 =
| width2 = | width2 =
| drug_name =
| imagename = <!-- else may use drug_name -->
| drug_name = <!-- else may use imagename -->


<!--Clinical data--> <!--Clinical data-->
Line 24: Line 26:
| legal_status = | legal_status =
| dependency_liability = | dependency_liability =
| routes_of_administration = | routes_of_administration =

<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
Line 31: Line 32:
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =

<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 405060-95-9 | CAS_number = 405060-95-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J8PSF5Z8KJ
| CAS_supplemental = | CAS_supplemental =
| ATCvet = | ATCvet =
Line 40: Line 43:
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =
| PubChem = | PubChem = 5717801
⚫ | DrugBank =
| PubChemSubstance =
⚫ | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| IUPHAR_ligand =
⚫ | ChemSpiderID = 4654442
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChEBI_Ref = {{ebicite|changed|EBI}}
⚫ | DrugBank =
| ChEBI = 131923
⚫ | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
⚫ | ChemSpiderID =
| synonyms = | ChEMBL = 180127
| synonyms =

<!--Chemical data--> <!--Chemical data-->
| chemical_formula = | chemical_formula =
| C=21 | H=17 | Cl=3 | N=4 | O=1 | S=1 | C=21 | H=17 | Cl=3 | N=4 | O=1 | S=1
| SMILES = C1=CC=C(C=C1)/C=C/C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3
| molecular_weight = 479.81 <ref name="cdata1"/><ref name="cdata2"/>
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| smiles =
| StdInChI = 1S/C21H17Cl3N4OS/c22-21(23,24)19(27-17(29)12-11-14-6-2-1-3-7-14)28-20(30)26-16-10-4-8-15-9-5-13-25-18(15)16/h1-13,19H,(H,27,29)(H2,26,28,30)/b12-11+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = LCOIAYJMPKXARU-VAWYXSNFSA-N
| density = | density =
| melting_point = | melting_point =
Line 65: Line 71:
}} }}


'''Salubrinal''' is a drug which acts as a specific inhibitor of ] ] enzymes<ref name="jl1"/><ref name="dk1"/><ref name="bm1"/> and is primarily used experimentally, to study stress responses in ] ]s associated with the action of eIF2. Salbrinal indirectly inhibits eIF2 as a result of reduced ] of its α-],<ref name="entrez1"/> resulting in activation of stress response pathways usually triggered by events such as ] or buildup of unfolded ] in the ].<ref name="rw1"/> Salubrinal has putative ] value due to its function,<ref name="jl1"/><ref name="bm1"/> but is as yet only used experimentally. Salubrinal is being studied at Indiana University for its potential to fight osteoporosis and accelerate bone healing.<ref name="seet1"/> '''Salubrinal''' is a drug which acts as a specific inhibitor of ] ] enzymes<ref name="jl1"/><ref name="dk1"/><ref name="bm1"/> and is primarily used experimentally, to study stress responses in ] ]s associated with the action of eIF2. Salubrinal indirectly inhibits eIF2 as a result of reduced ] of its α-],<ref name="entrez1"/> resulting in activation of stress response pathways usually triggered by events such as ] or buildup of unfolded ] in the ].<ref name="rw1"/> Salubrinal has putative ] value due to its function,<ref name="jl1"/><ref name="bm1"/> but is as yet only used experimentally. Salubrinal is being studied at Indiana University for its potential to fight osteoporosis and accelerate bone healing.<ref name="seet1"/>

⚫ == References ==
{{Portal|Medicine}}
⚫ {{Reflist|refs=

<ref name="dk1">{{cite journal | vauthors = Kessel D | title = Protection of Bcl-2 by salubrinal | journal = Biochemical and Biophysical Research Communications | volume = 346 | issue = 4 | pages = 1320–3 | date = August 2006 | pmid = 16806073 | pmc = 2978664 | doi = 10.1016/j.bbrc.2006.06.056 | publisher = Elsevier Inc }}{{dead link|date=March 2019|bot=medic}}{{cbignore|bot=medic}}</ref>

⚫ <ref name="jl1">{{cite journal | vauthors = Lewerenz J, Maher P | title = Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression | journal = The Journal of Biological Chemistry | volume = 284 | issue = 2 | pages = 1106–15 | date = January 2009 | pmid = 19017641 | pmc = 2613630 | doi = 10.1074/jbc.M807325200 | publisher = The American Society for Biochemistry and Molecular Biology, Inc | doi-access = free }}</ref>

⚫ <ref name="bm1">{{cite journal | vauthors = Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J | display-authors = 6 | title = A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress | journal = Science | volume = 307 | issue = 5711 | pages = 935–9 | date = February 2005 | pmid = 15705855 | doi = 10.1126/science.1101902 | bibcode = 2005Sci...307..935B | s2cid = 86257684 | url = http://www.sciencemag.org/cgi/content/abstract/307/5711/935 }}</ref>

⚫ <ref name="entrez1">{{cite web|title=Entrez Gene: EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa|url=https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1965|access-date=2010-10-05|publisher= ], U.S. National Library of Medicine}}</ref>

⚫ <!-- <ref name="cdata1">{{cite web|title=SALUBRINAL &#124; 405060-95-9|url=http://www.chemicalbook.com/ChemicalProductProperty_EN_CB3322523.htm|access-date=2010-10-05|publisher=ChemicalBook}}</ref> -->

⚫ <!-- <ref name="cdata2">{{cite web|url=http://datasheets.scbt.com/sc-202332.pdf|title=Salubrinal: sc-202332|date=2010-07-28|access-date=2010-10-05|publisher=Santa Cruz Biotechnology, Inc}}</ref> -->

<ref name="rw1">{{cite journal | vauthors = Wek RC, Jiang HY, Anthony TG | title = Coping with stress: eIF2 kinases and translational control | journal = Biochemical Society Transactions | volume = 34 | issue = Pt 1 | pages = 7–11 | date = February 2006 | pmid = 16246168 | doi = 10.1042/BST20060007 | publisher = Biochemical Society }}</ref>

⚫ <ref name="seet1">{{cite web | title=New compound may accelerate bone healing, prevent osteoporosis| url = http://www.cloningresources.com/research/New_compound_may_accelerate_bone_healing_prevent_osteoporosis.asp | archive-url = https://web.archive.org/web/20110929162126/http://www.cloningresources.com/research/New_compound_may_accelerate_bone_healing_prevent_osteoporosis.asp | archive-date = 29 September 2011 |access-date=2011-08-29 |date=August 2011}}</ref>


⚫ ==References==
⚫ {{Reflist|2|refs=
<ref name="dk1">{{cite journal|url=http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WBK-4K714XJ-5&_user=10&_coverDate=08%2F11%2F2006&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_searchStrId=1485420146&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=6afae3548902ab4fd881629a079b171b&searchtype=a|accessdate=2010-10-05|first=David|last=Kessel|publisher=Elsevier Inc|date=2006-08-11|page=1320|volume=346|issue=4|title=Protection of Bcl-2 by sulubrinal|journal=Biochemical and Biophysical Research Communications|doi=10.1016/j.bbrc.2006.06.056|pmid=16806073}}</ref>
⚫ <ref name="jl1">{{cite journal|title=Basal Levels of eIF2α Phosphorylation Determine Cellular Antioxidant Status by Regulating ATF4 and xCT Expression|journal=]|volume=284|issue=2|page=1106|date=2009-01-09|publisher=The American Society for Biochemistry and Molecular Biology, Inc|first1=Jan|last1=Lewerenz|first2=Pamela|last2=Maher|doi=10.1074/jbc.M807325200}}</ref>
⚫ <ref name="bm1">{{cite journal|author=Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J|title=A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress|journal=]|volume=307|issue=5711|pages=935–9|year=2005|month=February|pmid=15705855|doi=10.1126/science.1101902|url=http://www.sciencemag.org/cgi/content/abstract/307/5711/935|accessdate=2010-10-05}}</ref>
⚫ <ref name="entrez1">{{cite web|title=Entrez Gene: EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa|url=http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1965|accessdate=2010-10-05|publisher= ], U.S. National Library of Medicine}}</ref>
⚫ <ref name="cdata1">{{cite web|title=SALUBRINAL &#124; 405060-95-9|url=http://www.chemicalbook.com/ChemicalProductProperty_EN_CB3322523.htm|accessdate=2010-10-05|publisher=ChemicalBook}}</ref>
⚫ <ref name="cdata2">{{cite web|url=http://datasheets.scbt.com/sc-202332.pdf|title=Salubrinal: sc-202332|date=2010-07-28|accessdate=2010-10-05|publisher=Santa Cruz Biotechnology, Inc}}</ref>
<ref name="rw1">{{cite journal|title=Coping with stress: eIF2 kinases and translational control|url=http://www.biochemsoctrans.org/bst/034/0007/0340007.pdf|accessdate=2010-10-05|year=2006|month=February|authors=Wek R, Jiang H, Anthony T|journal=]|pages=7–11|pmid=16246168|volume=34|issue=1|publisher=Biochemical Society}}</ref>
⚫ <ref name="seet1">{{cite web | title=New compound may accelerate bone healing, prevent osteoporosis| url = http://www.cloningresources.com/research/New_compound_may_accelerate_bone_healing_prevent_osteoporosis.asp |accessdate=2011-29-08 |year=2011 |month=august}}</ref>
}} }}


Line 83: Line 99:
] ]
] ]


{{pharma-stub}}

Latest revision as of 17:08, 21 January 2025

Chemical compound Pharmaceutical compound
Salubrinal
Identifiers
IUPAC name
  • 3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino)thioxomethyl]amino]ethyl]-2-propenamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.237.268 Edit this at Wikidata
Chemical and physical data
FormulaC21H17Cl3N4OS
Molar mass479.80 g·mol
3D model (JSmol)
SMILES
  • C1=CC=C(C=C1)/C=C/C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3
InChI
  • InChI=1S/C21H17Cl3N4OS/c22-21(23,24)19(27-17(29)12-11-14-6-2-1-3-7-14)28-20(30)26-16-10-4-8-15-9-5-13-25-18(15)16/h1-13,19H,(H,27,29)(H2,26,28,30)/b12-11+
  • Key:LCOIAYJMPKXARU-VAWYXSNFSA-N
  (what is this?)  (verify)

Salubrinal is a drug which acts as a specific inhibitor of eIF2α phosphatase enzymes and is primarily used experimentally, to study stress responses in eukaryotic cells associated with the action of eIF2. Salubrinal indirectly inhibits eIF2 as a result of reduced dephosphorylation of its α-subunit, resulting in activation of stress response pathways usually triggered by events such as oxidative stress or buildup of unfolded protein in the endoplasmic reticulum. Salubrinal has putative therapeutic value due to its function, but is as yet only used experimentally. Salubrinal is being studied at Indiana University for its potential to fight osteoporosis and accelerate bone healing.

References

  1. ^ Lewerenz J, Maher P (January 2009). "Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression". The Journal of Biological Chemistry. 284 (2). The American Society for Biochemistry and Molecular Biology, Inc: 1106–15. doi:10.1074/jbc.M807325200. PMC 2613630. PMID 19017641.
  2. Kessel D (August 2006). "Protection of Bcl-2 by salubrinal". Biochemical and Biophysical Research Communications. 346 (4). Elsevier Inc: 1320–3. doi:10.1016/j.bbrc.2006.06.056. PMC 2978664. PMID 16806073.
  3. ^ Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, et al. (February 2005). "A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress". Science. 307 (5711): 935–9. Bibcode:2005Sci...307..935B. doi:10.1126/science.1101902. PMID 15705855. S2CID 86257684.
  4. "Entrez Gene: EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa". National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 2010-10-05.
  5. Wek RC, Jiang HY, Anthony TG (February 2006). "Coping with stress: eIF2 kinases and translational control". Biochemical Society Transactions. 34 (Pt 1). Biochemical Society: 7–11. doi:10.1042/BST20060007. PMID 16246168.
  6. "New compound may accelerate bone healing, prevent osteoporosis". August 2011. Archived from the original on 29 September 2011. Retrieved 2011-08-29.
Categories:
Salubrinal: Difference between revisions Add topic